Hemotune raises 14 million Swiss francs

Hemotune, a medtech firm based in Schlieren in the canton of Zurich, has closed a Series B2 financing round in the amount of 14 million Swiss francs. The investment process was led by Belmondo, with support coming from VP Venture Partners, HEMEX, Occident, Zürcher Kantonalbank (ZKB; the cantonal bank of Zurich,) and the Geneva-based investment firm EFI, further details of which can be found in a press release. This investment should now allow hemotune to move its blood purification system known as the HemoSystem into clinical trials, as the company explains in the press release.

Hemotune, which was founded as spin-off from the Swiss Federal Institute of Technology in Zurich (ETH), has been successful with its system in removing large biomolecules directly from the bloodstream. The use of the HemoSystem initially focuses on treating sepsis-related immune suppression, although the company does also plan to explore other potential applications. With 11 million deaths attributable to severe cases of sepsis, the technology developed by hemotune has the potential to offer important benefits to both patients and healthcare systems

“I am immensely proud of our team’s achievements in concluding the preclinical development of the HemoSystem”, comments Lukas Langenegger, CEO and co-founder of hemotune AG, in the press release, adding that: “As we navigate through a challenging fundraising climate, the success of our Series B2 funding round underscores not only the potential of our innovative blood purification platform but also the confidence our backers have in our team and vision to revolutionize medical treatment”. Dr. Darius Madjdpour, founder of Belmondo, is impressed by the development of hemotune over the past seven years: “We are happy to support the team for further journey and will be excited to see the product spread globally and help many patients over the coming years”, he concludes. ce/ww